Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan study finds in-stent restenosis susceptibility markers:

This article was originally published in Clinica

Executive Summary

A Japanese team has identified gene markers that could predict which patients who receive bare metal stents are more likely to develop in-stent restenosis. Researchers from the Gifu Prefectural Tajimi Hospital assessed 461 unrelated Japanese individuals who underwent coronary stent implantation, of which 107 subjects went on to develop in-stent restenosis. The genotypes for 142 polymorphisms of 121 candidate genes were determined using a method that combines polymerase chain reaction and sequence-specific oligonucleotide probes with suspension array technology. The BCHE, GPX1, and ROS1 genotypes were found to be independently associated with in-stent restenosis, the researchers revealed at last week's European Society of Cardiology 2007 meeting in Vienna, Austria.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT049678

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel